Maynard Um
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX)
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX): "we expect investor interest to grow"
-
-
-
-
-
-
-
Piper Sandler: 'We see substantial upside potential for Edgewise Therapeutics (EWTX)'
-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Edgewise Therapeutics (EWTX)
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), PT $50
-
-
-
-
-
-
-
Edgewise Therapeutics, Inc. (EWTX) Reports In-Line Q4 EPS
-
422,931 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

